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The C–C chemokine receptor-7 (CCR7) is a G protein coupled receptor that has a role in
leukocyte homing, but that is also expressed in aggressive tumor cells. Preclinical research
supports that CCR7 is a valid target in oncology. In view of the increasing availability of
therapeutic monoclonal antibodies that carry cytotoxic cargoes, we studied the feasibility
of forcing intact cells to internalize known monoclonal antibodies by exploiting the cycle
of endocytosis and recycling triggered by the CCR7 agonist CCL19. Firstly, an anti-CCR7
antibody (CD197; clone 150503) labeled surface recombinant CCR7 expressed in intact
HEK 293a cells and the ﬂuorescent antibody was internalized following CCL19 treatment.
Secondly, a recombinant myc-tagged CCL19 construction was exploited along the anti-myc
monoclonal antibody 4A6. The myc-tagged ligand was produced as a conditioned medium
of transfectedHEK 293a cells that contained the equivalent of 430 ng/ml of immunoreactive
CCL19 (average value, ELISA determination). CCL19-myc, but not authentic CCL19, carried
the ﬂuorophore-labeled antibody 4A6 into other recipient cells that expressed recombinant
CCR7 (microscopy, cytoﬂuorometry).The immune complexes were apparent in endosomal
structures, co-localized well with the small GTPase Rab5 and progressed toward Rab7-
positive endosomes. A dominant negative form of Rab5 (GDP-locked) inhibited this
endocytosis. Further, endosomes in CCL19-myc- or CCL19-stimulated cells were positive
for β-arrestin2, but rarely for β-arrestin1. Following treatment with CCL19-myc and the 4A6
antibody, the melanoma cell line A375 that expresses endogenous CCR7 was speciﬁcally
stained using a secondary peroxidase-conjugated antibody. Agonist-stimulated CCR7 can
transport antibody-based cargoes, with possible therapeutic applications in oncology.
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INTRODUCTION
C–C chemokine receptor-7 (CCR7) is a G protein coupled recep-
tor (GPCR) submitted to a cycle of endocytosis and recycling,
more so if stimulated with the chemokine CCL19 than with the
alternate agonist CCL21 (Otero et al., 2006). This is possibly due
to the selective recruitment of β-arrestins by CCL19 (Byers et al.,
2008). CCR7 is naturally expressed by naïve T cells, dendritic
cells, and a subset of natural killer cells and chemotactically sup-
ports the homing of these cells to lymph node paracortex, due
to the expression of CCL19 and CCL21 by lymph node stromal
cells (Maghazachi, 2010; Moschovakis and Förster, 2012; Weber
et al., 2013). CCR7 expression is generally upregulated during an
immune response in these cells and the accumulation and reten-
tion of T cells at chronic inﬂammatory sites is dependent on
CCR7 signaling (Moschovakis and Förster, 2012). The expres-
sion of CCR7 can evade the hemopoietic lineages in pathologies
such as rheumatoid arthritis (synovial ﬁbroblasts), scleroderma,
and cancer (Müller et al., 2001; Moschovakis and Förster, 2012).
First discovered in breast cancer cell lines (Müller et al., 2001),
CCR7 expression has been also observed in many solid tumors
and hematopoietic malignancies that have a propensity to migrate
to lymph nodes. These include classical Hodgkin disease, gastric
and head and neck carcinomas (Höpken et al., 2002; Mashino
et al., 2002; Wang et al., 2005). Tumor cell chemotaxis mediated
by CCR7 signaling is well documented and explains the metastatic
homing to lymph nodes (Shields et al., 2007b; Fang and Hwang,
2009). Melanoma is a paramount example of a malignancy that
acquires CCR7 expression in the metastatic state, as shown by the
human A375 cell line variants: high expression of the chemokine
receptor predicts the propensity for metastasis (Shields et al.,
2007a).
Current preclinical research supports that CCR7 is a valid
drug target in oncology (Fang and Hwang, 2009). For instance,
Chemotrap-1 is a soluble macromolecule not related to CCR7, but
that binds CCL21 with high afﬁnity and prevents the metastatic
extension of melanoma in animals (Lanati et al., 2010). How-
ever, the therapeutic effect of this biotechnological agent has
not been demonstrated against primary tumors and established
metastases.
In view of the increasing availability of therapeutic monoclonal
antibodies that carry cytotoxic cargoes, we studied the feasibility
of forcing intact cells to internalize known monoclonal antibodies
by exploiting the cycle of endocytosis and recycling triggered by
theCCR7 agonist CCL19. Firstly, an anti-CCR7 (CD197) antibody
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was tested in intact cells optionally stimulated with CCL19 treat-
ment. Secondly, a recombinant myc-tagged CCL19 construction
was exploited along the anti-myc monoclonal antibody 4A6. We
are currently developing a platform of bifunctional myc-tagged
peptide agonists of GPCRs that are suitable for coupling with both
anti-myc monoclonal antibodies (such as the 4A6 clone) and their
receptors. The receptor-mediated endocytosis of agonist–antibody
complexes in excess of 150 kDa has been demonstrated for the
bradykinin B2 receptor (Gera et al., 2013) and the parathyroid
hormone PTH1R (Charest-Morin et al., unpublished data), sug-
gesting that the approach can be generalized and exploited toward
the functional cargoes. As for parathyroid hormone, but unlike
bradykinin, the N-terminal sequence of CCL19 needs to be intact
to preserve a good afﬁnity for the cognate receptor (Ott et al.,
2004). Thus, we have exploited a CCL19 sequence C-terminally
extended with the myc epitope.
MATERIALS AND METHODS
CELL CULTURE, TRANSFECTION, AND ANALYSIS
A subclone of HEK 293 cells, called HEK 293a, originally obtained
from Sigma-Aldrich was used in many experiments. This cell type
was grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), 1% L-glutamine,
and 1% penicillin–streptomycin stock solutions (100×). HEK
293a cells were grown and transiently transfected as described
(Bawolak et al., 2011) with a vector coding for CCR7 (wild
type in pcDNA3, Otero et al., 2006; gift from Dr. Daniel F.
Legler, University of Konstanz, Germany). Using these cells,
a ﬁrst CCR7 imaging strategy was based on staining intact
and live HEK 293a cells previously transfected with the vec-
tor encoding for the receptor with carboxyﬂuorescein-conjugated
monoclonal anti-human CCR7 (CD197; clone 150503, ﬁnal con-
centration 5 μg/ml; R&D Systems, Minneapolis, MN, USA).
The cell distribution of the receptor was assessed after a 30-
min stimulation period with the agonist CCL19 (incubation at
37◦C).
Other HEK 293a cells were used as producer cells for a
secreted protein coded by vector purchased from OriGene Tech-
nologies (Rockville, MD, USA): myc-DDK-tagged prepro-CCL19,
that directs the secretion of the mature human CCL19 sequence
extended at its C-terminus with two epitopes in tandem, myc,
and DDK (catalog number RC506523). The latter construction
will be conventionally designated as CCL19-myc. Conﬂuent pro-
ducer cells (70%) were transfected with a given vector using either
the ExGen (Fermentas) or TurboFect (Thermo Scientiﬁc) reagents
used as directed. Conditioned medium (CM) was collected after
4 days of culture. The concentration of CCL19-myc was estimated
using a commercial ELISA kit for human CCL19 (Sigma-Aldrich,
catalog no. RAB0052). The CM samples were diluted 1000- to
10,000-fold for this test.
The secondCCR7visualization strategy involved recipientHEK
293a cells were grown and transiently transfected as described
above with the vector coding for CCR7 and optionally co-
transfected with the fusions proteins Rab5-Cherry, Rab5-GTP-
locked-Cherry ﬂuorescent protein, Rab5-GDP-locked-CherryFP,
Rab7-CherryFP (given by Dr. M. J. Tremblay, Université Laval,
Canada; Charest-Morin et al., 2013), or β-arrestin1-CherryFP
(kind gift from Dr. J.-M. Beaulieu, Université Laval, Canada).
Other cells were transfected with a sole vector coding for β-
arrestin2-green ﬂuorescent protein (GFP; gift from Dr. Michel
Bouvier, Université de Montréal). Stimulations for microscopic
or cytoﬂuorometric experiments were based on the CM of the
CCL19-myc construction supplemented with AlexaFluor-488-
conjugated monoclonal antibodies (clone 4A6, Millipore, dilution
1:1000 corresponding to aﬁnal antibody concentrationof approxi-
mately 3.3 nM in the culturemedium). Cells were generally treated
for 30 min with stimulants (incubation carried out at 37◦C in
humidiﬁed atmosphere containing 5% CO2), rinsed three times
with phosphate buffered saline, observed in microscopy for epiﬂu-
orescence, and photographed using anOlympus BX51microscope
coupled to a CoolSnap HQ digital camera (ﬁlters for GFP and
AlexaFluor-488: excitation460–500nm, emission510–560nm; for
Cherry ﬂuorescent protein: excitation 525–555 nm, emission 600–
660 nm). The objective lens was generally the 100× oil UPlanApo
(Olympus).
Other transfected HEK 293a cells were detached using the
protease-free Cell Dissociation Buffer (Invitrogen), incubated in
DMEM without serum at 37◦C for 30 min under agitation in the
presence of a stimulant, rapidly centrifuged (30 s, 15,000 g) and
resuspended in phosphate buffered saline. Then, the ﬂuorescence
of the cell suspensions was assessed using the BD SORP LSR II cell
analyzer (BD Biosciences, Franklin Lakes, NJ, USA) for the uptake
of a green ﬂuorophore as a function of stimulation and trans-
gene expression; results were analyzed using the BD FACS DIVA
software.
MELANOMA CELLS
The human melanoma A375, originally obtained from ATCC, was
a gift from Dr. Fawzi Aoudjit (CHU de Québec, Québec, Canada).
The cells were cultured in RPMI 1640 medium supplemented
with 10% FBS and antibiotics at 37◦C in a 5% CO2 humidiﬁed
atmosphere. This line is originally derived from a metastatic site
(Shields et al., 2007a) and is tumorigenic in immunodeﬁcientmice
(McMahon et al., 2001). To evidence the presence of CCR7, A375
cell mRNA was isolated with the Trizol reagent (Invitrogen) and
was treated 30 min with DNase1 (Roche) to avoid genomic DNA
contamination. cDNA were produced with 2 μg of isolate RNA
and MMLV reverse transcriptase (Invitrogen). Some samples were
also made without enzyme (RT-), as negative control for DNA
contamination. To evaluate the presence of cell transcription of
CCR7, 2 μl of cDNAs were ampliﬁed by PCR with Platinum Pfx
DNApolymerase (Invitrogen, 35 cycles). Oligos used for theCCR7
ampliﬁcation were: forward 5′-gcaatgggctggtcgtgttgac-3′; reverse
5′-caccttgatggccttgttgcgc-3′. Half of PCR products were revealed
by agarose electrophoresis.
The agonist-stimulated uptake of the anti-myc antibody
was tested as follows: A375 cells were incubated for 30 min
(37◦C) in the CCL19-myc or control CM supplemented with
the non-labeled 4A6 monoclonal antibody (Millipore, ﬁnal
concentration ≈ 3.3 nM). Then, cells were ﬁxed, perme-
abilized, and stained with the Tyramide Signal Ampliﬁcation
(TSA) Kit containing horseradish peroxidase (HRP) conjugated
goat anti-mouse IgG antibodies and AlexaFluor-488-tyramide
as a ﬂuorogenic co-substrate of the reaction (Invitrogen kit
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T20912 used as directed). Then a microphotographic record of
cell epiﬂuorescence and transmission was obtained as outlined
above.
IMMUNOBLOTS
The agonist action of CCL19-related agonists was investigated
using the expression of the transcription factor c-Fos, a distal
response to the stimulation of various receptor-ligand systems
(Glauser and Schlegel, 2007). Total A375 cell extracts were
immunoblotted to detect c-Fos expression using the K-25 rab-
bit polyclonal antibodies (Santa Cruz Biotechnology; dilution
1:50,000).
DATA ANALYSIS
Numerical values are reported as means ± SEM. Non-normally
distributed groups of values were analyzed using non-parametric
analysis of variance (Kruskal–Wallis test) followed by Dunn’s mul-
tiple comparison test. Normal sets of values were compared using
ANOVAfollowedbyDunnett’s test for comparisonwith a common
control value. In A375 cells stained with the TSA technique, the
mean ﬂuorescence intensity was determined in manually outlined
cells using the Photoshop software (version 6, Adobe Systems,
Mountain View, CA, USA) in multiple ﬁelds. Proportions of
labeled cells or organelles in response to treatments were com-
pared using the χ2 test (InStat 3.05 computer program, GraphPad
Software, San Diego, CA, USA).
RESULTS
CCL19-INDUCED INTERNALIZATION OF CCR7-ANTI-CCR7 IN HEK 293a
CELLS
Whether a commercial anti-CD197 antibody could support imag-
ing of CCR7 expressed in intact HEK 293a cells has been tested
(Figure 1). In resting cells, the associated ﬂuorescence was sharply
deﬁned at the level of the plasma membrane with no intra-
cellular signal, as expected from the exclusion of the antibody
from the cytosol. There was no signal in non-transfected cells,
suggesting that the antibody reacts with extracellular domain(s)
of the non-denatured CCR7. Adding CCL19 concentration-
dependently determined the translocation of a fraction of
the cell surface ﬂuorescence to ill-deﬁned cytosolic struc-
tures, consistent with agonist-induced receptor internalization
(Figure 1).
CHARACTERIZATION OF THE CMs
The CM of producer HEK 293a cells transfected with the
CCL19-myc vector contained the equivalent of 430 ng/ml of
immunoreactive CCL19 (average of three values: 150, 300, and
840 ng/ml). Three control CM of untransfected cells contained
none.
INTERNALIZATION OF myc-TAGGED CCL19-ANTI-myc IMMUNE
COMPLEXES IN HEK 293a CELLS
The second scheme for the visualization of CCR7 endocytosis
was based on the myc-tagged agonist co-incubated with a ﬂu-
orescent anti-myc antibody in the culture medium (Figure 2,
epiﬂuorescence microscopy; Figure 3, cytoﬂuorometry of cells
sequentially detached and stimulated). Controls included cells
that did not express CCR7, cells stimulated with authentic CCL19
FIGURE 1 | Internalization of fluorescein isothiocyanate-conjugated
monoclonal anti-human CCR7 induced by recombinant CCL19 in intact
HEK 293a cells that express recombinant CCR7. nt, non-transfected cells.
(1 μg/ml) or with the CM of untransfected HEK 293 cells.
A speciﬁc endosomal labeling of recipient cells that expressed
the receptor was observed in cells stimulated with CCL19-myc
(Figure 2), leading to a signiﬁcantly higher mean cell ﬂuo-
rescence (Figure 3). These observations provide evidence that
the CCL19-myc-4A6 immune complexes formed in the culture
medium were recognized as agonists by the fraction of cells
that expressed CCR7, and were transported into endosomes.
Authentic CCL19 devoid of the myc epitope was not compe-
tent to induce the endocytosis (pinocytosis) of droplets of the
culture medium containing the ﬂuorescent antibody, providing
additional evidence for the speciﬁc molecular interaction of the
myc-tagged agonist with the antibody. Cells untreated with the
ﬂuorescent anti-myc antibody had mean ﬂuorescence intensity
identical to the ﬁve control conditions in Figure 3, suggest-
ing that the control cells exhibited only the autoﬂuorescence
level.
TheCCL19-myc/4A6 co-stimulation schemewas used to inves-
tigate β-arrestin endosomal co-localization studies (Figure 4).
The Cherry-tagged β-arrestin1 is expressed as a homogeneous
cytosolic protein in recipient cells that co-expressed CCR7. Nei-
ther authentic CCL19 nor CCL19-myc CM induced signiﬁcant
condensation of β-arrestin1-Cherry into endosomal structures
5–30 min after stimulation; however, the immune complexes were
effectively detected at this level as the green particles (see statistics
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FIGURE 2 | Endocytosis of the anti-myc monoclonal antibody (clone
4A6, conjugated to AlexaFluor-488, final concentration in the culture
medium 3.3 nM) as determined by co-treatment with the CCL19-myc
construction in intact HEK 293a cells that optionally and transiently
expressed CCR7. A control conditioned medium (CM) or authentic CCL19
were used as control stimuli. The undiluted CM were transferred for a
30-min incubation period before rinsing and observation. Original
magniﬁcation ×1000.
in Figure 4 legend). The alternate construction β-arrestin2-GFP
was co-expressed with CCR7 in other HEK 293a cells and stim-
ulated without the 4A6 antibody (also green light emitting). It
was observed that the resting smooth cytosolic distribution of
this arrestin isoform was condensed into endosomal structures
revealed by treatments with CCL19-myc (5–30 min) or with
authentic CCL19 (Figure 5), producing further support for a
selective afﬁnity of activated CCR7 for one of the non-visual
arrestins.
Other HEK 293a cells that expressed CCR7 were also co-
transfected with one of three Rab5-Cherry constructions: the
fusion protein consisting of the wild type Rab5, the GTP-locked
activated one that causes the formation of giant endosomes
where cargo accumulates (Stenmark et al., 1994), or the domi-
nant negative GDP-locked Rab5 (Figure 6). Co-localization was
observed in cells treated for 30 min with the CM of CCL19-
myc in cells expressing Rab5-Cherry (arrowheads; this concerned
19.1% of green organelles in a sample of 89 from 10 cells).
The GTP-locked construction induces the formation of giant
vacuoles where the green ﬂuorescence of the CCL19-myc/anti-
myc-antibody complexes was extensively trapped (Figure 6;
88.3% of green organelles were circled by a red lining; sam-
ple of 43 from 11 cells). The GDP-locked Rab5 construction
FIGURE 3 | Cytofluorometry of HEK 293a cells that optionally
expressed CCR7, sequentially detached and further stimulated with
the undiluted CM of other cells producing CCL19-myc, authentic
CCL19, or CM of untransfected cells, as indicated (30 min incubation
at 37◦C). Left: distributions based on the counting of 10,000 cells. A
threshold of autoﬂuorescence was deﬁned using control cells with no
ﬂuorophore. It was surpassed only under one set of experimental
conditions (arrow). Right: mean ﬂuorescence of cells in replicated
experiment. ANOVA indicated that the values were heterogeneous
(p < 10−4). *p < 0.01 vs. top-most value (control CM, untransfected
recipient cells) by Dunnett’s test.
rather suppressed the endocytosis of immune complexes (aver-
age of 2.1 ± 0.9 green specs per cell in 10 cells treated with
CCL19-myc CM, comparable to the value of control CM in
Figure 5).
Rab5 is a marker of early endosomes, whereas Rab7 rather
labels late endosomes and lysosomes. Minor co-localization of
the CCL19-myc/anti-myc-antibody complexes was observed after
either 30-min (5.3% of green endosomes) or 3-h treatments
(12.6% of green endosomes; Figure 7), indicating a slow progress
of the antibody cargo in the endosomal/lysosomal tract as these
proportions signiﬁcantly differ (p < 0.05, χ2-test; sample of 11
cells for each treatment duration containing totals of 189 and 175
green endosomes, respectively).
CCR7 IN METASTATIC MELANOMA CELLS
RT-PCR provided evidence for the presence of CCR7-mRNA in
a human melanoma cell line, the A375 line (Figure 8A). The
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FIGURE 4 | Epifluorescence microscopy studies in cells co-expressing
β-arrestin1-Cherry and CCR7 and stimulated as indicated (stimulant
and duration). Stimulation always included the ﬂuorescent anti-myc
monoclonal antibody 4A6 (green signal). Either CCL19-myc CM or authentic
CCL19 rarely condensed β-arrestin1 at the level of plasma membranes of
endosomes (arrowhead indicates possible co-localization with the
CCL19-myc-antibody cargo). Cells that expressed well the red-emitting
transgene were assumed to co-express co-transfected CCR7 and were
evaluated for morphology (n = 16–49 eligible cells per group). The average
number of red condensed structures was 0.4 ± 0.4 in cells treated with
control CM and did not vary signiﬁcantly in all other groups (Kruskal–Wallis
test). The average number of green condensed structures in cells treated
with control CM was 0 per cell and varied signiﬁcantly according to
treatments (p < 10−4, Kruskal–Wallis test; p values for Dunn’s multiple
comparison test for each value vs. that of control CM reported thereafter).
There were 8.3 ± 1.7 green specs per cell (p < 0.05), 25.8 ± 3.2
(p < 0.001), 33.1 ± 4.4 (p < 0.001), and 0 (N.S.) in cells treated with
CCL19-myc CM for 5, 10, or 30 min, or with recombinant CCL19,
respectively.
receptor is functional, as shown by c-Fos induction observed in
response to 1 h of stimulation with CCL19-myc CM, but not with
control CM (Figure 8B).
TheA375 cells didnot support the endosomal stainingobserved
in HEK 293 cells that overexpress CCR7 and are co-treated
with CCL19-myc + the ﬂuorescent anti-myc antibody (as in
Figure 2, data not shown). However, an enzymatic ampliﬁca-
tion scheme reveals the apparent speciﬁc uptake of CCL19-myc
co-incubated with the non-ﬂuorescent 4A6 monoclonal (TSA
imaging: Figure 9). Negative controls included stimulations
with the antibody combined with the control CM, authentic
CCL19, or a myc-tagged parathyroid hormone, PTH1−84-myc
(prepared as a CM in cells transfected with the OriGene vector
FIGURE 5 | Epifluorescence microscopy studies in cells co-expressing
CCR7 and β-arrestin2-GFP and stimulated as indicated (stimulant and
duration). Stimulation did not include the ﬂuorescent anti-myc antibody.
Either CCL19-myc CM or authentic CCL19 frequently condensed
β-arrestin2 at the level of plasma membrane or endosomes. Right: number
of green intracellular condensed structures (“specs”) per cell ± SEM.
Numbers close to bars indicate the number of evaluated HEK 293a cells.
The Kruskal–Wallis test indicated that the values were heterogenous
(p < 10−4). The effect of each treatment vs. the effect of control CM was
evaluated using Dunn’s multiple comparison test. *p < 0.01; **p < 0.001.
RC519848 and containing the equivalent of ∼180 ng/ml of the
hormone).
DISCUSSION
By exploiting two commercially available monoclonal antibod-
ies, we have illustrated that the human recombinant CCR7
receptor can internalize such large proteins when stimulated with
the agonist CCL19. The anti-receptor antibody clone 150503
recognized an extracellular epitope in non-denatured CCR7
expressed by intact cells (Figure 1) and, as such, was internal-
ized with the stimulated receptor. Furthermore, the antibody
did not inhibit the interaction of CCR7 with its agonist lig-
and. This experimental system is similar to that consisting of
the N-terminally tagged myc-B2 receptor for bradykinin, that
bound the anti-myc 4A6 monoclonal antibody and internalized
immune complexes built around this antibody at the surface of
intact cells upon stimulation with bradykinin (Bawolak et al.,
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FIGURE 6 | Epifluorescence microscopy studies in cells co-expressing
one of three forms of Rab5-Cherry fusion proteins and CCR7 and
stimulated for 30 min with either CCL19-myc or control CM.
Co-localization between Rab5-positive corpuscles and the CCL19-
myc-antibody cargo was observed (arrowheads). The dominant positive
(GTP-locked) mutant of the fusion protein produced typical giant vacuoles
that included the green light-emitting cargo. The dominant negative
Rab5-GDP-locked-Cherry inhibited the endocytosis of the green cargo (see
text for numerical analysis).
2011). Data from these studies provide strong evidence that
GPCR-mediated endocytosis can transport extremely large MDa
cargoes, such as secondary antibodies bound to Qdot nanoma-
terials.
The second strategy exploited a myc-tagged agonist along with
the anti-myc monoclonal antibody 4A6. It was hypothesized that
the CCL19-myc construction, but not authentic CCL19, could
carry anti-myc antibodies to endosomes. The myc tag is a 10-
residue sequence that is widely used in recombinant protein
constructs, and also in a synthetic bradykinin homolog that car-
ried the 4A6 antibody into cells that expressed the bradykinin B2
receptor, albeit with low efﬁcacy due to the low receptor afﬁn-
ity of the bifunctional peptide (Gera et al., 2013). The present
system is more favorable as the CM of cells transfected with the
CCL19-myc vector, which contains an average immunoreactive
concentration (430 ng/ml), compares well with concentrations
of authentic CCL19 needed to internalize CCR7 (Figure 1) or
FIGURE 7 | Epifluorescence microscopy studies in cells co-expressing
Rab7-Cherry and CCR7 and stimulated as indicated (stimulant and
duration). Co-localization between Rab7-positive corpuscles and the
CCL19-myc-antibody cargo was not highly frequent (arrowheads), but
increased in frequency as a function of incubation duration (see text for
numerical analysis).
FIGURE 8 | Presence of CCR7 in A375 melanoma cells. (A) RT-PCR for
CCR7 in the human melanoma A375 cell line. (B) c-Fos induction in A375
cells stimulated as indicated for 1 h (typical immunoblot and histograms
representing the densitometry of replicated experiments).
condense β-arrestin2-GFP into endosomes (Figure 5). Thus, the
C-terminal extension of CCL19 with antigenic tags produced no
signiﬁcant effect on receptor afﬁnity, as predicted from the cur-
rent ligand docking model (Ott et al., 2004), and there is no
apparent steric hindrance between antibody-bound CCL19-myc
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FIGURE 9 | Detection of endogenous CCR7 in A375 cells using
detection of the endocytosed CCL19-myc-4A6 antibody complex using
theTyramide Signal Amplification (TSA) system that enzymatically
generates AlexaFluor-488 labeling. Epiﬂuorescence and transmission,
original magniﬁcation: ×1000. Right: proportion of cells with a mean
ﬂuorescence intensity above a set threshold (Photoshop level ≥ 50/255) in
large photographic records of A375 cells stained as in the left of ﬁgure (the
number of evaluated cells is indicated next to each histogram). The
proportions were compared with that of control cells without antibody
(top-most histogram, χ2 test; *p < 10−4).
and the CCR7. The immune complexes, composed of a diva-
lent antibody, may be quite large (in excess of 150 kDa) and are
not taken up by activated cells by pinocytosis, as the non-tagged
agonist CCL19 does not support the internalization of the 4A6
antibody added to the culture medium. Furthermore, PTH1−84-
myc, another construction of a size comparable to CCL19-myc
and also tagged at its C-terminus, failed to support endocytosis of
the anti-myc antibody in A375 cells, producing evidence that an
intimate trimolecular reaction (CCL19-myc + 4A6 + CCR7) at
the extracellular side of the receptor is necessary for endocytosis
of the antibody cargo.
C-terminal extension of CCL19 has also been illustrated under
the form of a ∼80 kDa dimeric CCL19-IgG Fc fusion protein
that was a functional CCR7 agonist (calcium signaling, chemo-
taxis; Otero et al., 2006). Previous evidence, based in part on
this construction and ﬂuorescent CCR7, established that the lig-
and, rapidly co-localized with the receptor and transferrin in
recycling endosomes, progressed slowly toward lysosomes (Otero
et al., 2006). Consistent with these ﬁndings, we observed a slow
transition of the 4A6 antibody initially bound to CCL19-myc
to Rab7-positive organelles (late endosomes and/or lysosomes).
Also, the dynamin and clathrin-dependent endocytosis of CCL19
(Otero et al., 2006) was found to be Rab5-dependent because
GDP-locked Rab5 suppressed the endocytosis of the CCL19-myc-
4A6 immune complexes. GDP-locked Rab5 also suppressed the
endocytosis of the activated bradykinin B2 receptor in a recent
study (Charest-Morin et al., 2013). Furthermore, receptor phos-
phorylation should occur prior to the internalization of CCR7
and indirect evidence of this is provided by the condensation
of cytosolic β-arrestins into endosomal structures (Figures 4
and 5). Stimulated CCR7 may have a preference for β-arrestin2
over β-arrestin1, as the mCherry-tagged form of the latter was
rarely found in endosomes where the CCL19-4A6 complexes were
translocated. This asymmetry in the role of the two non-visual
arrestins had been previously observed using a gene knockout
approach (Byers et al., 2008) and contrasts with the activated
bradykinin B2 receptor, equally capable of associating with both
forms (also used as ﬂuorescent protein conjugates; Gera et al.,
2012).
The metastatic melanoma A375 cell line possesses a func-
tional endogenous population of CCR7 (Figure 8; Shields et al.,
2007a) that also supported the uptake of a small amount of anti-
myc antibody complexed to CCL19-myc, relative to cells that
expressed recombinant CCR7 at high density. At the risk of tem-
porarily enhancing migration, survival and invasion (Fang and
Hwang, 2009), but perhaps with the beneﬁt of sensitizing cells
to anti-mitotic agents, CCR7 stimulation with a tagged agonist
in oncology may allow the β-arrestin-dependent endocytosis of a
cytotoxic cargo, such as an antibody conjugated to maytansinoids
or others high potency cytotoxic drugs. This could kill tumor cells
with some selectivity if the cytotoxic cargo is allowed to enter
the endocytic pathway even in very small quantities (Teicher and
Doroshow, 2012). An alternative application could be the killing
of CCR7-positive dendritic cells, which form long lasting reser-
voirs for HIV that preclude viral eradication (Zhang and Perelson,
2013), and of infected CD4+ T cells, in which CCR7 activation
may contribute to the nuclear integration of the HIV genome
(Cameron et al., 2010).
In addition to the endocytosis of anti-CCR7 antibody trig-
gered by CCL19, the present studies indicate the feasibility of the
speciﬁc cellular uptake of an immune complex consisting of a
tagged agonist of CCR7 and of the anti-myc antibody. The latter
approach is essentially modular, as the same anti-myc antibody
can be transported in cell expressing various types of receptors
by varying the identity of the myc-tagged agonist (Gera et al.,
2013; Charest-Morin et al., unpublished data). One can imagine a
formof personalized treatmentwhere the tagged agonist is selected
according to the repertoire of internalized receptors, whether or
not GPCRs, expressed by a given malignancy.
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